Clene (NASDAQ:CLNN) Major Shareholder Sells $119,889.25 in Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 24,925 shares of the business’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $4.81, for a total value of $119,889.25. Following the transaction, the insider owned 401,891 shares in the company, valued at $1,933,095.71. This represents a 5.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Wednesday, April 1st, Chidozie Ugwumba sold 4,278 shares of Clene stock. The shares were sold at an average price of $4.97, for a total value of $21,261.66.
• On Tuesday, February 3rd, Chidozie Ugwumba sold 5,559 shares of Clene stock. The shares were sold at an average price of $4.10, for a total value of $22,791.90.
• On Monday, February 2nd, Chidozie Ugwumba sold 3,800 shares of Clene stock. The shares were sold at an average price of $4.04, for a total value of $15,352.00.
• On Friday, January 30th, Chidozie Ugwumba sold 5,686 shares of Clene stock. The shares were sold at an average price of $4.13, for a total value of $23,483.18.
• On Thursday, January 29th, Chidozie Ugwumba sold 15,284 shares of Clene stock. The shares were sold at an average price of $4.32, for a total value of $66,026.88.
• On Wednesday, January 28th, Chidozie Ugwumba sold 8,717 shares of Clene stock. The shares were sold at an average price of $4.91, for a total value of $42,800.47.
• On Tuesday, January 27th, Chidozie Ugwumba sold 4,139 shares of Clene stock. The shares were sold at an average price of $5.08, for a total value of $21,026.12.
• On Monday, January 26th, Chidozie Ugwumba sold 6,418 shares of Clene stock. The shares were sold at an average price of $5.02, for a total value of $32,218.36.
• On Friday, January 23rd, Chidozie Ugwumba sold 5,556 shares of Clene stock. The shares were sold at an average price of $5.27, for a total value of $29,280.12.
• On Thursday, January 22nd, Chidozie Ugwumba sold 12,665 shares of Clene stock. The shares were sold at an average price of $5.32, for a total value of $67,377.80.

Clene Trading Up 2.2%

CLNN stock opened at $6.40 on Thursday. Clene Inc. has a 1-year low of $2.28 and a 1-year high of $13.50. The firm has a market cap of $75.39 million, a P/E ratio of -2.46 and a beta of 0.62. The business’s 50 day moving average is $5.05 and its 200-day moving average is $6.65.

Clene (NASDAQ:CLNN) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.14). The firm had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.03 million. Sell-side analysts forecast that Clene Inc. will post -5.19 EPS for the current year.

Institutional Investors Weigh In On Clene

Large investors have recently bought and sold shares of the business. Ensign Peak Advisors Inc grew its position in Clene by 668.6% during the 4th quarter. Ensign Peak Advisors Inc now owns 114,361 shares of the company’s stock worth $671,000 after acquiring an additional 99,481 shares during the last quarter. SymBiosis Capital Partners LLC bought a new stake in Clene during the 4th quarter worth approximately $4,523,000. Geode Capital Management LLC grew its position in Clene by 8.0% during the 4th quarter. Geode Capital Management LLC now owns 82,079 shares of the company’s stock worth $482,000 after acquiring an additional 6,090 shares during the last quarter. Scoggin Management LP grew its position in Clene by 75.1% during the 3rd quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock worth $1,506,000 after acquiring an additional 107,250 shares during the last quarter. Finally, PEAK6 LLC bought a new stake in Clene during the 4th quarter worth approximately $294,000. 23.28% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

CLNN has been the topic of several analyst reports. D. Boral Capital reiterated a “buy” rating and issued a $23.00 price objective on shares of Clene in a research note on Thursday, March 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Clene in a research report on Friday, January 9th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $48.00 price target on shares of Clene in a research report on Friday, March 13th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Clene has a consensus rating of “Moderate Buy” and a consensus target price of $33.00.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).